$PFE Company News Pfizer anti-cholesterol drug meets main

New Post Public Reply Private Reply Replies (0) Message Board

Mar 27, 2014 at 10:56 AM

$PFE Company News

Pfizer anti-cholesterol drug meets main study goal 9:28 a.m. Today - MarketWatch.com
Apple looks ready to head higher 3:48 p.m. March 17, 2014 - blogs.marketwatch.com
Apple as the Comeback Kid 1:13 p.m. March 13, 2014 - Mark Hulbert
Mylan to start selling generic Celebrex in May 7:22 a.m. March 13, 2014 - MarketWatch.com
Pfizer loses Celebrex patent ruling; shares halted but effect muted 3:21 p.m. March 12, 2014 - blogs.marketwatch.com
Pfizer loses ruling on Celebrex patent dispute 2:46 p.m. March 12, 2014 - Russ Britt
Trading resumes on Pfizer shares 2:37 p.m. March 12, 2014 - Russ Britt
Ruling invalidates Pfizer's Celebrex patent 2:36 p.m. March 12, 2014 - Russ Britt
Pfizer obtained reissue patent on Celebrex in 2013 2:35 p.m. March 12, 2014 - Russ Britt
Pfizer plans to appeal ruling on Celebrex judgment 2:31 p.m. March 12, 2014 - Russ Britt
Pfizer loses ruling on Celebrex patent dispute 2:30 p.m. March 12, 2014 - Russ Britt
Pfizer halted 2:15 p.m. March 12, 2014 - Steve Goldstein
S&P 500 extends the break to ‘clear skies’ territory 10:46 a.m. March 6, 2014 - Michael Ashbaugh
Newscast: Stocks take a spill to start the week 4:26 p.m. March 3, 2014 - MarketWatch
Pfizer aims to sell over-the-counter version of Lipitor 8:13 a.m. March 3, 2014 - Peter Loftus
Newscast: Pfizer moves to make Lipitor OTC 7:39 a.m. March 3, 2014 - MarketWatch
Best stocks for legalized marijuana 1:37 p.m. Feb. 27, 2014 - blogs.marketwatch.com
Pfizer pneumonia vaccine study meets objectives 7:45 a.m. Feb. 24, 2014 - MarketWatch.com
You'd have to be a dope to buy marijuana stocks 1:36 p.m. Feb. 13, 2014 - blogs.marketwatch.com
Australia regulator takes action against Pfizer 11:03 p.m. Feb. 12, 2014 - MarketWatch.com

Pfizer's Bococizumab cuts "bad" cholesterol in mid-stage study 9:32 a.m. Today - Seeking Alpha
The Richest Man In History Reveals His Simple Wealth Generating Secret 8:56 a.m. Today - Seeking Alpha
Wall Street Breakfast: Must-Know News 6:32 a.m. Today - Seeking Alpha
Novartis lung-cancer drug produces response in over half of patients 4:26 a.m. Today - Seeking Alpha
The Only 20 Companies That Matter 8:03 p.m. March 26, 2014 - Seeking Alpha
Positive Data on Halozyme Candidate - Analyst Blog 6:50 p.m. March 26, 2014 - Zacks.com
ARIAD Candidate in Phase II Study - Analyst Blog 6:10 p.m. March 26, 2014 - Zacks.com
10 Healthcare Dogs Prescribe 6% To 16% March Upsides 5:59 p.m. March 26, 2014 - Seeking Alpha
Novartis Drug Shows Promise in Rare Lung Cancer 5:20 p.m. March 26, 2014 - The Wall Street Journal Interactive Edition
Pfizer Gains Slightly on Xalkori Data - Analyst Blog 5:16 p.m. March 26, 2014 - Zacks.com
Which Drugmaker Will Snap Up Merck’s Consumer Health Unit? 4:58 p.m. March 26, 2014 - Wall St. Cheat Sheet
Dow Drops Amid Soft Underlying Durable Goods 4:28 p.m. March 26, 2014 - TheStreet.com
Top Stock Picks From an Index-Crushing Manager 10:50 a.m. March 26, 2014 - Barrons.com
Stock Market News for March 26, 2014 - Market News 10:06 a.m. March 26, 2014 - Zacks.com
Big pharma investing in regenerative medicine 8:33 a.m. March 26, 2014 - Seeking Alpha
Pfizer's Genotropin meets main goal in Phase IIIb study 8:33 a.m. March 26, 2014 - Seeking Alpha
Telecoms Liven Up Short Interest in Big Dividend Stocks 8:15 a.m. March 26, 2014 - 247WallSt.com
J.P. Morgan Says Buy Specialty and Big Pharmaceuticals Now 8:15 a.m. March 26, 2014 - 247WallSt.com
Pharma & Biotech Stock Outlook - March 2014 - Zacks Analyst Interviews 2:17 a.m. March 26, 2014 - Zacks.com
Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook 2:17 a.m. March 26, 2014 - Zacks.com

In A Subanalysis, The Benefits Of Eliquis® (apixaban) Vs. Warfarin In Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation Were Consistent, Regardless Of Blood Pressure Control 1 8:16 a.m. Today - BusinessWire - BZX
Bococizumab (RN316) Significantly Reduced LDL Cholesterol In Statin-Treated Adults With High Cholesterol In A Phase 2b Study1 8:02 a.m. Today - BusinessWire - BZX
Pfizer Achieves Primary Endpoint With Phase 3B Top-Line Results Of GENOTROPIN® In Very Young Children Born Small For Gestational Age 8:01 a.m. March 26, 2014 - BusinessWire - BZX
Pfizer Invites Public To View And Listen To Webcast Of May 5 Conference Call With Analysts 5:10 p.m. March 25, 2014 - BusinessWire - BZX
Pfizer Reports Positive Phase 3 Study Outcome Of XALKORI® (crizotinib) Compared To Chemotherapy In Previously Untreated Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) 8:30 a.m. March 25, 2014 - BusinessWire - BZX
Renaissance Technologies Buys Stake in Pfizer; Yahoo Looks to Profit from Alibaba IPO 12:21 a.m. March 25, 2014 - ACCESSWIRE
Pfizer Announces Detailed Results of OPT Compare Phase 3 Study of Tofacitinib 5 mg and 10 mg Twice Daily Compared to High-Dose ENBREL® in Adults with Moderate-to-Severe Chronic Plaque Psoriasis 11:45 a.m. March 22, 2014 - BusinessWire - BZX
Healthcare Companies Report Acquisitions, Upcoming Results Schedules, Dividends, and Annual Reviews - Analyst Notes on Pfizer, Magellan Health Services, Prothena, Alere, and KYTHERA 8:00 a.m. March 21, 2014 - PR Newswire - PRF
Pfizer’s Investigational Vaccine Candidate Bivalent rLP2086 Receives U.S. Food and Drug Administration Breakthrough Therapy Designation for Potential Prevention of Meningococcal B Disease 8:31 a.m. March 20, 2014 - BusinessWire - BZX
Healthcare Companies Report FDA Approvals, Comprehensive Analysis, Schedules, and Stock Movements - Analyst Notes on Pfizer, Johnson & Johnson, Biogen, Express Scripts, and Forest Laboratories 8:00 a.m. March 20, 2014 - PR Newswire - PRF
Avanir Pharmaceuticals Announces Appointment of Mark Corrigan to Board of Directors 4:00 p.m. March 19, 2014 - PR Newswire - PRF
ViiV Healthcare Announces Next Round of the Positive Action Southern Initiative to Support Linkages to HIV/AIDS Care and Treatment Adherence 9:45 a.m. March 19, 2014 - PR Newswire - PRF
Insider Trading Research - Alerts for Microsoft, Oracle, Pfizer, Plug Power, Sirius XM, and Bank of America 8:55 a.m. March 19, 2014 - PR Newswire - PRF
Portola Pharmaceuticals Initiates Phase 3 Study of Andexanet Alfa, Potential First-in-Class Factor Xa Inhibitor Reversal Agent, Under Accelerated Approval Pathway 8:15 a.m. March 19, 2014 - GlobeNewswire
Pfizer Launches 2013 Integrated Annual Review 10:00 a.m. March 18, 2014 - BusinessWire - BZX
Healthcare Companies Receive Approvals, Recognitions, Agreements, and Announce Senior Level Appointments- Analyst Notes on Pfizer, Boston Scientific, WellPoint, Aetna, and Humana 8:00 a.m. March 18, 2014 - PR Newswire - PRF
U.S. FDA Approves Eliquis® (apixaban) To Reduce The Risk Of Blood Clots Following Hip Or Knee Replacement Surgery 1:00 p.m. March 14, 2014 - BusinessWire - BZX
Insider Trading Alert - Research Report on Facebook, Intel, Yahoo, Plug Power, FuelCell Energy, and Pfizer 8:55 a.m. March 14, 2014 - PR Newswire - PRF
Pfizer Will Appeal Court Decision Regarding Celebrex Reissue Patent 2:28 p.m. March 12, 2014 - BusinessWire - BZX
Pfizer Announces Webcast Of April 6 Conference Call With Securities Analysts To Review Palbociclib Phase 2 Final Results Following Presentation At AACR Annual Meeting 2014 10:01 a.m. March 12, 2014 - BusinessWire - BZX

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

EZRA Loop Fuses Human Insight and AI for Managers

Hybrid Coaching: The Future is Here If someone told me five years ago that human coaches and AI would team up to churn out better business leaders, I'd have a laugh. But here we are with EZRA Loop, an inventive mix of flesh-and-blood wisdom and algorithmic precision hitting the streets. This might seem like the latest buzzword pie in the sky to some, but there's a real...

AI Deepfakes Met Their Match: IC-Corp's New Patent

The Deepfake Fraud Reality Slap You know, in a world where you can't trust your own eyes on a video call, trust gets a bit sketchy, right? Imagine this scenario—an unsuspecting finance employee, surrounded by familiar faces and voices, only to wind up sending $25.6 million to fraudsters who weren't even real. A chilling real-world example from January 2024, courtesy of...

Landis+Gyr's Big Contract Victory: A Game Changer?

Diving into Landis+Gyr's Major Utility Win When news hits about a deal secured by Landis+Gyr Group AG, it rings a few bells across the utility landscape. These folks have brewed up a storm with a fresh contract that slots into their rapidly expanding portfolio of grid-savvy products. So, what’s the fuss about this latest agreement? A Groundbreaking Contract Now, this...

Better Home & Finance Faces 28.5% Stock Plunge, Lawsuit

The Sudden Dive in Better Home's Stock Imagine cruising down the highway with the wind in your hair and suddenly slamming into a pothole. That's the kind of jarring experience Better Home & Finance Holding Company (NASDAQ: BETR) investors felt when the stock took a nosedive, diving a hefty 28.5%. Back on May 7, 2026, the company released financial figures that flipped the...

Touchmark's Q3 Bonanza: Income Leaps 39%, Stock Repurchase

Ever seen a bank juggle financials like a street performer with flaming torches? That's Touchmark Bancshares for you this quarter. This Georgia-based community bank just released their third quarter 2026 results, and it seems they've not only mastered performance but also pranced around market risks effortlessly, much to the delight of investors. Breaking Down the Numbers...

Fair Play in Focus: SYNA, CSR, VCTR, EFSI Deals Scrutinized

The Corporate Buzz: Deals Under the Microscope Riding the rollercoaster of mergers and acquisitions ain't new in the stock market realm. But when the stakes seem one-sided, alarms start ringing. Halper Sadeh LLC, a firm that cuts its teeth on this kind of corporate sleuthing, is all hands on deck probing a slew of big deals involving Synaptics (NASDAQ:SYNA), Centerspace...

SoftwareOne Secures Leadership in Gartner Report Again

A Glance at SoftwareOne's Unyielding Dominance Call it a streak, call it consistency—either way, SoftwareOne's nailed it yet again, bagging the Leader spot in Gartner's Magic Quadrant for SAM Managed Services for the seventh straight year. Yep, seven years running. This ain't just a piece of paper to hang on the office wall. It's a testament to their grit in helping...

Essential Oils Market Booms; Hits $29.52Bn by 2031

Essential Oils: Aromatherapy's New Frontier and Pharma Ally What’s the deal with essential oils? Well, it seems they’re not just for your neighbor’s pricey diffuser anymore. According to some fresh numbers, we're staring down a market worth nearly $30 billion by 2031. And it ain't all incense and hippie stores fueling this beast — we're talking a serious expansion...

Infosys Faces EPS Miss, Legal Scrutiny for Investors

Infosys' Earnings Struggle When even a penny's worth of expectations falls short, the market isn't going to simply shrug it off. This was the case for Infosys Limited (NYSE: INFY) after they managed to miss analysts' earnings projections by a mere cent. On October 23, 2026, they revealed a second-quarter earnings report showing $0.20 per share, which was a penny below...

Century Communities Unveils New Homes Near Austin

New Opportunities in the Lone Star State Century Communities, Inc. (NYSE: CCS) is cranking up the heat in the real estate market with their latest attraction—Crosswinds in Kyle, Texas. This isn't just another cookie-cutter development; it's packing in excitement with a grand opening on October 28. From model home tours to early-bird savings, they're pulling out all the...